Inserm Transfert, Inserm’s private subsidiary specialized in technology transfer.

Pascal Aage – Chairman of the Board of Inserm Transfert

Inserm Transfert, a privately owned subsidiary of Inserm, part of the Public Service Delegation, specialized in technology transfer in the healthcare field. Meeting with Pascal Auger, Chairman of the Board of Inserm Transfert.

What is the mission of Inserm Transfert?

Our mission is based on innovation and the advancement of research results. Inserm also ranks among the top three in terms of pharmaceutical or biotech innovation according to the European Patent Office. Specifically, Inserm Transfert is a team of around 100 people dedicated exclusively to development, innovation and co-financing.

How do you support researchers?

In innovation, it all starts with finding local sources to understand their research and their results. We then support them in their smart defense strategy. Then comes the proof-of-concept phase, an activity we are developing and in which Inserm has invested 22 million euros since 2009. This made it possible to implement about 300 projects. We are also in the business of partnering with industrialists and entrepreneurs (to support the drive to create researchers as early as possible). Finally, we support researchers in their search for national or European funding.

What is the profile of these researchers?

It can be young or more experienced researchers, clinicians from Inserm or other partner institutions (CNRS), or academic researchers (universities) representing a diverse source of research power! Their topics are diverse: new drug approaches, diagnostic or prognostic solutions for diseases, and digital health solutions.

Are partnerships with researchers important to you?

Obviously ! To bring a product to market, we certainly need industrial relays, from start-ups to large groups. Manufacturing restrictions, regulations, and advanced clinical trials are rather the core business of the industry. In short, we provide additional and necessary skills. Again, this is an important advantage for advancing clinical staging and enabling solutions to be marketed to the benefit of patients.

Can you give examples of successful partnerships?

We contributed to the creation of SME HalioDx, which aims to improve the diagnosis of cancer patients using Immunoscore®. This SME was purchased by the international group Veracyte. We also participated in the launch of iBox, a predictive algorithm for renal allograft survival marketed by startup Cibiltech, which has revolutionized practice internationally. Finally, Professor Guillaume Canauud, who identified the causative phenomena that cause Carnation syndrome, found a new target for which Novartis developed a molecule at the clinical stage. In April 2022, a new drug was released in the US.

So what are your long term goals?

Continue to expand our work on innovation to make it a source of national sovereignty. We are also part of national government-driven healthcare acceleration strategies that include, but are not limited to, emerging infectious diseases, biotherapy and biomanufacturing, and digital health.